Changing anticoagulant paradigms for atrial fibrillation: Dabigatran, apixaban and rivaroxaban

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 4, 2011, Pages 567-577

  Giorgi, Mariano A ^a,b   Cohen Arazi, Hernán ^a   Gonzalez, Claudio D ^b,c   Di Girolamo, Guillermo ^d,e  

^a FLENI   (Argentina)

^b UNIVERSIDAD AUSTRAL   (Argentina)

^c CEMIC   (Argentina)

^d UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^e FAVALORO UNIVERSITY   (Argentina)

Author keywords

Anticoagulant; Apixaban; Atrial fibrillation; Dabigatran; Direct thrombin inhibitor; Factor Xa inhibitor; Rivaroxaban

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; AZD 0837; BARBITURIC ACID DERIVATIVE; BETRIXABAN; DABIGATRAN; DABIGATRAN ETEXILATE; DU 176 B; EDOXABAN; EFAVIRENZ; ERIBAXABAN; FLUCONAZOLE; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PANTOPRAZOLE; PHENPROCOUMON; PHENYTOIN; PROTON PUMP INHIBITOR; QUINIDINE; RIFAMPICIN; RIVAROXABAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; WARFARIN; XIMELAGATRAN; YM 150;

ANTICOAGULANT THERAPY; ARTERY EMBOLISM; BLEEDING; BRAIN HEMORRHAGE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DYSPEPSIA; EMBOLISM; FOOD DRUG INTERACTION; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; INTRAOCULAR HEMORRHAGE; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; PHARMACODYNAMICS; PHARMACOGENETICS; PROTHROMBIN TIME; RETROPERITONEAL HEMORRHAGE; REVIEW; STROKE; THROMBOSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; VEIN EMBOLISM; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; DRUG DESIGN; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDONES; THIOPHENES; THROMBOEMBOLISM; VITAMIN K;

EID: 79951688186     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.528754     Document Type: Review

References (80)

1. Schnabel RB, Sullivan LM, Levy D, et al. Developments of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 2009;373:739-45
2. Wolf PA, Benjamin EJ, Belanger AJ. Secular trends in the prevalence of atrial fibrillation: the Framingham Study. Am Heart J 1996;131:790-5 (Pubitemid 26116354)
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Heart Study. Stroke 1991;22:983-8
4. Nieuwlaat R, Prins MH, Le Heuzey JY, et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2008;29:1181-9 (Pubitemid 351844895)
5. Gage BF, Waterman AD, Shannon B, et al. Validation of clinical classification schemes for predicting stroke. Results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70 (Pubitemid 32537350)
6. Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Guidelines for the management of atrial fibrillation. Eur Heart J 2010;31(19):2369-429
7. Lip GY, Niewlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation. Chest 2010;137:263-72
8. Lip GY, Halperin JL. Improving stroke risk stratification in atrial fibrillation. Am J Med 2010;123:484-8
9. Poli D, Lip G, Antonucci E, et al. Stroke risk stratification in a 'real world' elderly anticoagulated atrial fibrillation population. J Cardiovasc Electrophysiol 23 Jul 2010. [Epub ahead of print]
10. Brunton LL, Parker LK. Blood coagulation and anticoagulant, thrombolytic, and antiplatelet drugs. In: Goodman & Gilman's manual of pharmacology and therapeutics. McGraw-Hill; 2008
11. Hart R.G. Pearce L.A. Aguilare M.I. (Pubitemid 351650486)
12. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in patients taking warfarin. Ann Intern Med 1994;120:897-902 (Pubitemid 24179151)
13. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted dose warfarin versus low intensity, fixed dose warfarin plus aspirin for high risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomised clinical trial. Lancet 1996;348:633-8
14. The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): a randomized controlled trial. Lancet 2006;367:1903-12
15. Mant J, Hobbs R, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomized controlled trial. Lancet 2007;370:493-503 (Pubitemid 47212371)
16. Cios DA, Baker WL, Sander SD, et al. Evaluating the impact of study-level factors on warfarin control in US primary-based studies: a meta-analysis. Am J Health Syst Pharm 2009;66:916-25
17. Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115:2689-96 (Pubitemid 46842784)
18. Poli D, Antonucci E, Grifoni E, et al. Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J Am Coll Cardiol 2009;54:999-1002
19. Pisters R, Lane DA, Nieuwlaart R, et al. A novel user friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey. Chest 2010;18:10-0134
20. Wu AH. Use of genetic and non-genetic factors in warfarin dosing algorithms. Pharmacogenomics 2007;7:851-61 (Pubitemid 47288981)
21. The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009;360:753-64
22. Bauer LA. Clinical pharmacokinetics and pharmacodynamics concepts. In: Bauer LA, editor, Clinical pharmacokinetcs handbook. McGraw-Hill; 2006. p. 3-18
23. Chaudhari D, Bhuriya R, Arora R. Newer anticoagulants as alternate to warfarin in atrial fibrillation: a changing paradigm. Am J Ther 10 May 2010 [Epub ahead of print]PMID: 20460986
24. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral venous thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009;48:1-22
25. Di Nisio M, Middledorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005;353:1028-40 (Pubitemid 41262337)
26. Hauel NH, Nar H, Priepke H, et al. Structure-based design of novel potent non-peptide thrombin inhibitors. J Med Chem 2002;45:1757-66 (Pubitemid 34415371)
27. European Medicines Agency. European public assessment report: p. Available from: www.emea.europa.eu/humandocs/ PDFs/EPAR/pradaxa/H-829-PI-en.pdf [Last accessed 25 May 2010]
28. Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:292-303 (Pubitemid 47283865)
29. Wienen W, Stassen JM, Priepke H, et al. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran, and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007;98:155-62 (Pubitemid 47078782)
30. Stangier J, Stahle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008;47:47-59 (Pubitemid 350260888)
31. Ufer M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost 2010;103:572-85
32. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with non valvular atrial fibrillation (PETRO Study). Am J Cardiol 2007;100:1419-26 (Pubitemid 47576022)
33. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
34. Bleech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug. Metab. Dispos. 2008;36:386-99 (Pubitemid 351185753)
35. Khoo CW, Lip GYH. Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial. Expert Opin Pharmacother 2010;11:685-7
36. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct factor Xa inhibitor. Thromb Haemost 2005;3:514-21 (Pubitemid 41632877)
37. European Medicines Agency. CHMP Assessment Report for Xarelto. Available from: www.ema.europa.eu/docs/en-GB/ document-library/EPAR-.-Public-assessment- report/human/000944/WC500057122.pdf [Last accessed 25 May 2010]
38. Weinz C, Radtke M, Schmeer K, et al. In vitro metabolism of BAY 59-7939 - an oral, direct factor Xa inhibitor [abstract 195]. Drug Metab Rev 2004;36(Suppl 1):98
39. Kubitza D, Becka M, Zuehlsdorf M, et al. Effect of food, an antiacid, and the H2 antagonist ranitidine on the absortion of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006;46:549-58
40. Kubitza D, Becka M, Roth A, et al. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 2008;24:2757-65
41. Tobu M, Iqbal O, Hoppensteadt D, et al. Anti-Xa and anti-IIa drugs alter international normalized ratio measurements: potential problems in the monitoring of oral anticoagulants. Clin Appl Thromb Hemost 2004;10:301-9 (Pubitemid 39391290)
42. Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005;61:873-80 (Pubitemid 41803696)
43. Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single dose of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005;78:412-21 (Pubitemid 41393676)
44. The Executive Steering Committee, on behalf of the ROCKET AF Study Investigators. Rivaroxaban-once daily, oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF Study. Am Heart J 2010;159:340-7
45. Pinto DJ, Orwat MJ, Koch S, et al. Discovery of 1-(4-methoxyphenyl)- 7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)- 4,5,6,7-tetrahydro 1H-pyrazolo3,4-c] pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2007;50:5339-56
46. He K, He B, Grace JE, et al. Preclinical pharmacokinetic and metabolism of apixaban, a potent and selective factor Xa inhibitor. Available from: www.abstracts.hematologylibrary.org/cgi/content/abstract/108/11/910?maxtoshow= &hits=10&RESULTFORMAT=&fulltext=apixaban&searchid= 1&FIRSTINDEX=0&volume=108&issue=11&resourcetype=HWCIT [Last accessed 28 February 2010]
47. Luettgen JM, Bozarth TA, Bozarth JM, et al. In vitro evaluation of apixaban, a novel, potent, selective and orally bioavailable factor Xa inhibitor [abstract 4130]. Available from: www.abstracts.hematologylibrary.org/cgi/ content/abstract/108/11/910?maxtoshow=&hits=10&RESULTFORMAT= &fulltext=apixaban&searchid=1&FIRSTINDEX=0&volume=108&issue= 11&resourcetype=HWCIT [Last accessed 28 February 2010]
48. Eikelboom JW, O'Donnell M, Yusuf S, et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heat J 2010;159:348-53
49. Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066-78
50. AVERROES Study of investigational agent apixaban closes early due to clear evidence of efficacy. Available from: http://www.bms.com/news/press- releases/pages/default.aspx [Last accessed 20 June 2010]
51. Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010;159:331-9
52. Oldgren J. Randomised dabigatran etexilate dose finding study in patients with acute coronary syndromes post index event with additional risk factors for cardiovascular complications also receiving clopidogrel. RE-DEEM. Presentad at the American Heart Association Scientific Sessions, 18 November 2009, Orlando, FL, USA. Available from: www.tctmd . com/show.aspx?id=87742[Last accessed 28 March 2010]
53. Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract 2010;64(7):956-67
54. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparine for prevention of venous thromboembolism after total hip replacement: a randomized, double blind, non-inferiority trial. Lancet 2007;370:949-56 (Pubitemid 47393577)
55. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparine for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-85 (Pubitemid 47617868)
56. Ginsberg IS, Davidson BI, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparine regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24:1-9
57. Alexander JH, Becker RC, Bhatt DL, et al. Apixaban, an oral direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention Of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009;119:2877-85
58. Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomized, double-blind, phase II trial. Lancet 2009;374:29-38
59. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2010;3:692-4 (Pubitemid 41647882)
60. Van Thiel D, Kalodiki E, Wahi E, et al. interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 mg) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery. Clin Appl Thromb Hemost 2009;15:389-94
61. Eriksson BI, Borris LC, Friedman RJ, et al. Roivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-75 (Pubitemid 351930851)
62. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double blind, randomized controlled trial. Lancet 2008;372:31-9
63. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty: N Engl J Med 2008;358:1776-86
64. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomized trial. Lancet 2009;373:1673-80
65. Wolowacz SE, Roskell NS, Plumb JM, et al. Efficacy and safety of dabigatran etixilate for the prevention of venous thromboembolism following hip or knee arthroplasty. A meta-analysis. Thromb Haemost 2009;101:77-85
66. Eriksson BI, Kakkar JK, Turpie AGG, et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg 2009;91:636-44
67. Sylvia H. Facts and artefacts of coagulation assays for factor Xa inhibitors. Thromb Haemost 2010;103:686-8
68. FDA panel supports approval of Pradaxa- (dabigatran etexilate) for stroke reduction in atrial fibrillation. Available from: http://www.nelm.nhs.uk/en/ NeLM-Area/News/2010-September/21/FDA-panel-supports-approval-of- Pradaxadabigatran-etexilate-for-stroke-reductionin-atrial-fibrillation/ [Last accessed 23 September 2010]
69. Schwarz UI, Rithchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during inityial anticoagulation. N Engl J Med 2008;358:999-1008 (Pubitemid 351347099)
70. Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009;113:784-92
71. Clarification of Optimal Anticoagulation Through Genetics (COAG) trial. Available from: http://clinicaltrials.gov/ct2/show/NCT00839657 [Last accessed 24 September 2010]
72. Oake N, Fergusson DA, Forster AJ. Frequency of adverse events in patients with poor anticoagulation: a metaanalysis. Can Med Assoc J 2007;176:1589-94 (Pubitemid 46868607)
73. Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy subjects and patients undergoing total hip replacement. J Clin Pharmacol 2005;45:555-63 (Pubitemid 40562946)
74. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008;47:285-95 (Pubitemid 351508116)
75. Weinz C, Schwarz T, Kubitza D, et al. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug. Metab. Dispos. 2009;37:1056-64
76. Weinz C, Buetehorn U, Daehler HP, et al. Pharmacokinetics of BAY 59-7939 - an oral, direct factor Xa inhibitor - in rats and dogs. Xenobiotica 2005;35:891-910 (Pubitemid 41759174)
77. Frost C, Yu Z, Nepal S, et al. Apixaban, a direct factor Xa inhibitor: single dose pharmacokinetics and pharmacodynamics of an intravenous formulations [abstract 142].J Clin Pharmacol 2008;48:1132
78. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug. Metab. Dispos. 2009;37:74-81
79. Frost C, Yu Z, Moore K, et al. Apixaban, an oral direct factor Xa inhibitor: multiple-dose safety, pharmacokinetics and pharmacodynamics in healthy subjects. J Thromb Haemost 2007;5(Suppl 2):P-M-664
80. Wang L, Raghavan N, He K, et al. Sulfation of o-demethyl apixaban: enzyme identification and species comparison. Drug. Metab. Dispos. 2009;37:802-8